Expert Panels are formed to provide professional support for DAC and DFC in the management of HA Drug Formulary. The number of Expert Panels may change as necessary.
Terms of Reference
a) In Support of DAC :
i) To provide expert opinions on introduction of new drugs, clinical guidelines or protocols upon request; and
ii) To nominate representatives as DAC members upon invitation.
b) In Support of DFC :
i) To conduct biennial comprehensive review of the HA Drug Formulary and consultation on drug issues upon request;
ii) To make recommendation on the proposed changes in the HA Drug Formulary;
iii) To advise on the use of alternatives for obsolete drugs; and
iv) To advise on appropriate use of unregistered and non-formulary drugs.
i) DFC Chairman and Chief Pharmacist
i) One representative of relevant COCs or CCs on disease groups;
ii) Seven cluster specialist representatives nominated by CCEs; and
iii) Two Cluster Clinical Stream Coordinators (Pharmacy) / Senior Pharmacists nominated by Chief Pharmacist.
Members’ tenure goes with the cycle of biennial comprehensive review of the HA Drug Formulary and all members can be re-appointed upon nomination by their respective CCEs, COCs / CCs on disease groups or Chief Pharmacist as appropriate.
List of Expert Panel on HA Drug Formulary
- Ear, Nose and Throat
- Family Medicine
- Human Immunodeficiency Virus Medicine
- Infectious Disease
- Medicine (Cardiology)
- Medicine (Endocrine and Diabetes Mellitus)
- Medicine (Gastrointestinal and Liver)
- Medicine (Haematology)
- Medicine (Neurology)
- Medicine (Renal)
- Medicine (Respiratory)
- Medicine (Rheumatology)
- Obstetrics and Gynaecology
- Orthopaedics and Traumatology